NXL103
Drug600mg orally twice daily
NCT Number: NCT00653172
The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 2
Clinica de Enfermedades Resp. "Miguel de Servet" SA, Santiago, Chile
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
600mg orally twice daily
comparator twice daily
Time frame: early follow up visit (day 14 to 21)
Time frame: early follow up visit (day 14 to 21)
Time frame: first dose, throughout treatment, and to follow up visit
Novexel Inc
Industry
A Double-Blind, Multicenter, Randomized, Double Dummy, Three-Arm Parallel-Group Comparative Study of the Efficacy, Safety and Tolerance of Oral NXL 103 Versus Oral Comparator in the Treatment of Community-Acquired Pneumonia in Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07425561
Bacterial Infections, Bacterial Infections and Mycoses
Florence, Italy
View Trial DetailsNCT07336121
Bronchial Diseases, Bronchiolitis
Cairo, Egypt
View Trial DetailsNCT02517489
Community Acquired Pneumonia, Community-Acquired Infections
Angoulême, France
View Trial DetailsNCT06210282
Community Acquired Pneumonia, Community-Acquired Infections
Gistrup, Denmark
View Trial Details